Identification of a xylosyltransferase II gene haplotype marker for diabetic nephropathy in type 1 diabetes

Clinica Chimica Acta

Volumn 398, Issue 1-2, 2008, Pages 90-94

  Hendig, Doris ^a   Tarnow, Lise ^b   Kuhn, Joachim ^a   Kleesiek, Knut ^a   Götting, Christian ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b STENO DIABETES CENTER   (Denmark)

Author keywords

Diabetic nephropathy; Genetic variations; Heparan sulfate proteoglycans; Polymorphisms; Type 1 diabetes; Xylosyltransferase II

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; XYLT2 GENE;

ADULT; ALLELES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DNA; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PENTOSYLTRANSFERASES; PHENOTYPE;

EID: 54049133987     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.08.019     Document Type: Article

References (34)

1. Martinez-Castelao A., De Alvaro F., and Gorriz J.L. Epidemiology of diabetic nephropathy in Spain. Kidney Int Suppl (2005) S20-S24
2. van Ittersum F.J., de Man A.M., Thijssen S., et al. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol Dial Transplant 15 (2000) 1000-1007
3. Fox C.S., Larson M.G., Leip E.P., Meigs J.B., Wilson P.W., and Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 28 (2005) 2436-2440
4. Hovind P., Tarnow L., and Parving H.H. Remission and regression of diabetic nephropathy. Curr Hypertens Rep 6 (2004) 377-382
5. Parving H.H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41 (1998) 745-759
6. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32 (1989) 219-226
7. van den Born J., van den Heuvel L.P., Bakker M.A., Veerkamp J.H., Assmann K.J., and Berden J.H. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41 (1992) 115-123
8. Scott P.G. Macromolecular constituents of basement membranes: a review of current knowledge on their structure and function. Can J Biochem Cell Biol 61 (1983) 942-948
9. Vernier R.L., Steffes M.W., Sisson-Ross S., and Mauer S.M. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 41 (1992) 1070-1080
10. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev 17 (2001) 412-421
11. Kjellen L., and Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 60 (1991) 443-475
12. Götting C., Kuhn J., and Kleesiek K. Human xylosyltransferases in health and disease. Cell Mol Life Sci 64 (2007) 1498-1517
13. Götting C., Kuhn J., Zahn R., Brinkmann T., and Kleesiek K. Molecular cloning and expression of human UDP-d-Xylose: proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II. J Mol Biol 304 (2000) 517-528
14. Pönighaus C., Ambrosius M., Carrera Casanova J., et al. Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. J Biol Chem 282 (2007) 5201-5206
15. Seo N.S., Hocking A.M., Hook M., and McQuillan D.J. Decorin core protein secretion is regulated by N-linked oligosaccharide and glycosaminoglycan additions. J Biol Chem 280 (2005) 42774-42784
16. Schön S., Huep G., Prante C., et al. Mutational and functional analyses of xylosyltransferases and their implication in osteoarthritis. Osteoarthr Cartil 14 (2006) 442-448
17. Schön S., Schulz V., Prante C., et al. Polymorphisms in the xylosyltransferase genes cause higher serum XT-I activity in patients with pseudoxanthoma elasticum (PXE) and are involved in a severe disease course. J Med Genet 43 (2006) 745-749
18. Götting C., Prante C., Schillinger M., et al. Xylosyltransferase I variants and their impact on abdominal aortic aneurysms. Clin Chim Acta 391 (2008) 41-45
19. Schön S., Prante C., Müller S., et al. Impact of polymorphisms in the genes encoding xylosyltransferase I and a homologue in type 1 diabetic patients with and without nephropathy. Kidney Int 68 (2005) 1483-1490
20. Schön S., Prante C., Bahr C., et al. The xylosyltransferase I gene polymorphism c.343G>T (p.A125S) is a risk factor for diabetic nephropathy in Type 1 diabetes. Diabetes Care 29 (2006) 2295-2299
21. Bahr C., Schön S., Kuhn J., et al. Novel sequence variants in the human xylosyltransferase I gene and their role in diabetic nephropathy. Diabet Med 23 (2006) 681-684
22. Kuhn J., Götting C., Schnölzer M., Kempf T., Brinkmann T., and Kleesiek K. First isolation of human UDP-D-xylose: proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells. J Biol Chem 276 (2001) 4940-4947
23. Cuellar K., Chuong H., Hubbell S.M., and Hinsdale M.E. Biosynthesis of chondroitin and heparan sulfate in chinese hamster ovary cells depends on xylosyltransferase II. J Biol Chem 282 (2007) 5195-5200
24. Voglmeir J., Voglauer R., and Wilson I.B. XT-II, the second isoform of human peptide-O-xylosyltransferase, displays enzymatic activity. J Biol Chem 282 (2007) 5984-5990
25. Lajer M., Tarnow L., Fleckner J., et al. Association of aldose reductase gene Z + 2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabet Med 21 (2004) 867-873
26. Tarnow L., Cambien F., Rossing P., et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44 (1995) 489-494
27. Skol A.D., Scott L.J., Abecasis G.R., and Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38 (2006) 209-213
28. Dupont W.D., and Plummer Jr. W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 11 (1990) 116-128
29. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
30. Müller S., Disse J., Schöttler M., et al. Human xylosyltransferase I and N-terminal truncated forms: functional characterization of the core enzyme. Biochem J 394 (2006) 163-171
31. Casanova J.C., Kuhn J., Kleesiek K., and Götting C. Heterologous expression and biochemical characterization of soluble human xylosyltransferase II. Biochem Biophys Res Commun 365 (2008) 678-684
32. Prante C., Milting H., Kassner A., et al. TGF-beta1 regulated xylosyltransferase I activity in human cardiac fibroblasts and its impact for myocardial remodeling. J Biol Chem 282 (2007) 26441-26449
33. Prante C., Bieback K., Funke C., et al. The formation of extracellular matrix during chondrogenic differentiation of mesenchymal stem cells correlates with increased levels of xylosyltransferase I. Stem Cells 24 (2006) 2252-2261
34. Müller B., Prante C., Gastens M., Kuhn J., Kleesiek K., and Götting C. Increased levels of xylosyltransferase I correlate with the mineralization of the extracellular matrix during osteogenic differentiation of mesenchymal stem cells. Matrix Biol 27 (2008) 139-149